As­traZeneca's Lyn­parza-Imfinzi com­bo hits pri­ma­ry end­point in PhI­II en­dome­tri­al can­cer tri­al DUO-E

As­traZeneca’s block­buster can­cer drugs Imfinzi and Lyn­parza are step­ping in­to a new in­di­ca­tion — first-line en­dome­tri­al can­cer — and sig­nif­i­cant­ly im­proved one of the dual pri­ma­ry end­points …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER